{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:44Z","timestamp":1790915024893,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is regulated by hypoxia-inducible factor (HIF). HIF2\u03b1 seems to be the principal regulator of EPO transcription, but HIF1\u03b1 and 3\u03b1 also may have additional influences on erythroid maturation. HIF is also involved in the regulation of iron, an essential component in erythropoiesis. Iron is essential for the organism but is also highly toxic, so its absorption and retention are strictly controlled. HIF also induces the synthesis of proteins involved in iron regulation, thereby ensuring the availability of iron necessary for hematopoiesis. Iron is a major component of hemoglobin and is also involved in erythrocyte differentiation and proliferation and in the regulation of HIF. Renal anemia is a condition in which there is a lack of stimulation of EPO synthesis due to decreased HIF expression. HIF prolyl hydroxylase inhibitors (HIF-PHIs) stabilize HIF and thereby allow it to be potent under normoxic conditions. Therefore, unlike erythropoiesis-stimulating agents, HIF-PHI may enhance iron absorption from the intestinal tract and iron supply from reticuloendothelial macrophages and hepatocytes into the plasma, thus facilitating the availability of iron for hematopoiesis. The only HIF-PHI currently on the market worldwide is roxadustat, but in Japan, five products are available. Clinical studies to date in Japan have also shown that HIF-PHIs not only promote hematopoiesis, but also decrease hepcidin, the main regulator of iron metabolism, and increase the total iron-binding capacity (TIBC), which indicates the iron transport capacity. However, concerns about the systemic effects of HIF-PHIs have not been completely dispelled, warranting further careful monitoring.<\/jats:p>","DOI":"10.3390\/ijms24033037","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T02:57:32Z","timestamp":1675652252000},"page":"3037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism"],"prefix":"10.3390","volume":"24","author":[{"given":"Chie","family":"Ogawa","sequence":"first","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, INC, Kawasaki 211-0063, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Biomarker Society, INC, Kawasaki 211-0063, Japan"},{"name":"Department of Blood Purification, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunimi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, INC, Kawasaki 211-0063, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of Anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic Kidney Disease Diagnosis and Management: A Review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sofue, T., Nakagawa, N., Kanda, E., Nagasu, H., Matsushita, K., Nangaku, M., Maruyama, S., Wada, T., Terada, Y., and Yamagata, K. (2020). Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236132"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lamerato, L., James, G., van Haalen, H., Hedman, K., Sloand, J.A., Tang, A., Wittbrodt, E.T., and Yee, J. (2022). Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: A retrospective observational study. BMC Nephrol., 23.","DOI":"10.1186\/s12882-022-02778-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000245041","article-title":"Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management","volume":"29","author":"Kanbay","year":"2010","journal-title":"Blood Purif."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"HIF-prolyl hydroxylase inhibitors in renal anemia: Current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv. Chronic. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cell.2014.01.069","article-title":"Heme-Mediated SPI-C Induction Promotes Monocyte Differentiation into Iron-Recycling Macrophages","volume":"156","author":"Haldar","year":"2014","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic Regulators of Iron Metabolism","volume":"133","author":"Ganz","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000496492","article-title":"Iron Deficiency Anemia in Chronic Kidney Disease","volume":"142","author":"Schechter","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mikhail, A., Brown, C., Williams, J.A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., and Bhandari, S. (2017). Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0688-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.14740\/jocmr3360w","article-title":"Elevated Neutrophil Gelatinase Lipocalin Levels Are Associated With Increased Oxidative Stress in Hemodialysis Patients","volume":"10","author":"Nevo","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1681\/ASN.2015010052","article-title":"The Labile Side of Iron Supplementation in CKD","volume":"26","author":"Slotki","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1182\/blood-2012-09-456079","article-title":"Qualitative analysis of murine terminal erythroid differentiation in vivo: Novel method to study normal and disordered erythropoiesis","volume":"121","author":"Liu","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V77.12.2583.2583","article-title":"Erythropoietin receptor characteristics on primary human erythroid cells","volume":"77","author":"Broudy","year":"1991","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0092-8674(95)90234-1","article-title":"Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor","volume":"83","author":"Wu","year":"1995","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat. Genet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00174.2010","article-title":"Hypoxic regulation of erythropoiesis and iron metabolism","volume":"299","author":"Haase","year":"2010","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/5979","article-title":"Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse","volume":"21","author":"Vulpe","year":"1999","journal-title":"Nat. Genet"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Richard, C., and Verdier, F. (2020). Transferrin Receptors in Erythropoiesis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249713"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.bbamcr.2016.09.008","article-title":"Erythroid cell mitochondria receive endosomal iron by a \u201ckiss-and-run\u201d mechanism","volume":"1863","author":"Hamdi","year":"2016","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1182\/blood-2010-11-319483","article-title":"Targeted deletion of the mouse mitoferrin1 gene: From anemia to protoporphyria","volume":"117","author":"Troadec","year":"2011","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ng1658","article-title":"Identificatio of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells","volume":"37","author":"Ohgami","year":"2005","journal-title":"Nat. Genet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","article-title":"Iron control of erythroid development by a novel aconitase-associated regulatory pathway","volume":"116","author":"Bullock","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-030-41769-7_14","article-title":"Hemoglobin: Structure, Function and Allostery","volume":"94","author":"Ahmed","year":"2020","journal-title":"Subcell Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Alnuwaysir, R.I.S., Hoes, M.F., van Veldhuisen, D.J., van der Meer, P., and Grote Beverborg, N. (2021). Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010125"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kawabata, T. (2022). Iron-Induced Oxidative Stress in Human Diseases. Cells, 11.","DOI":"10.3390\/cells11142152"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-007-2095-z","article-title":"Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular cartinoma from chronic hepatitis C","volume":"42","author":"Kato","year":"2007","journal-title":"J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1536\/ihj.46.255","article-title":"Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease","volume":"46","author":"Reis","year":"2005","journal-title":"Int. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/j.mam.2020.100864","article-title":"Iron in infection and immunity","volume":"75","author":"Nairz","year":"2020","journal-title":"Mol. Aspects Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol. Aspects Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ehf2.12797","article-title":"Anaemia, iron deficiency and heart failure in 2020: Facts and numbers","volume":"7","author":"Chopra","year":"2020","journal-title":"ESC Heart Fail"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/hdi.12542","article-title":"Overview of iron metabolism in health and disease","volume":"21","author":"Dev","year":"2017","journal-title":"Hemodial. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out Ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1074\/jbc.M111.310789","article-title":"BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice","volume":"287","author":"Patel","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.1021\/acsomega.2c01833","article-title":"Iron Absorption: Factors, Limitations, and Improvement Methods","volume":"7","author":"Piskin","year":"2022","journal-title":"ACS Omega"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1126\/science.1057206","article-title":"An iron regulated ferric reductase associated with the absorption of dietary iron","volume":"291","author":"McKie","year":"2001","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1172\/JCI24356","article-title":"Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver","volume":"115","author":"Gunshin","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2005.06.025","article-title":"Identification of an intestinal heme transporter","volume":"122","author":"Shayeghi","year":"2005","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","article-title":"Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption","volume":"127","author":"Qiu","year":"2006","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev.pharmtox.37.1.517","article-title":"The heme oxygenase system: A regulator of second messenger gases","volume":"37","author":"Maines","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmet.2005.01.003","article-title":"The iron exporter ferroportin\/Slc40a1 is essential for iron homeostasis","volume":"1","author":"Donovan","year":"2005","journal-title":"Cell. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1079\/PNS2004386","article-title":"The molecular basis of copper and iron interactions","volume":"63","author":"Sharp","year":"2004","journal-title":"Proc. Nutr. Soc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/biof.1148","article-title":"The regulation of iron transport","volume":"40","author":"Frazer","year":"2014","journal-title":"Biofactors"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1073\/pnas.95.3.1148","article-title":"Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport","volume":"95","author":"Fleming","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cmet.2015.05.002","article-title":"SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis","volume":"22","author":"Jenkitkasemwong","year":"2015","journal-title":"Cell. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2018.07.020","article-title":"DMT1 and iron transport","volume":"133","author":"Yanatori","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood.V88.8.3200.bloodjournal8883200","article-title":"Ferritin uptake by human erythroid precursors is a regulated iron uptake pathway","volume":"88","author":"Gelvan","year":"1996","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1097-2765(00)80282-8","article-title":"IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal. subunit by the cap-binding complex eIF4F","volume":"2","author":"Muckenthaler","year":"1998","journal-title":"Mol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1073\/pnas.93.16.8175","article-title":"Molecular control of vertebrate1iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress","volume":"93","author":"Hentze","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/35001596","article-title":"Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter","volume":"403","author":"Donovan","year":"2000","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1097-2765(00)80425-6","article-title":"A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation","volume":"5","author":"McKie","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jn\/133.5.1510S","article-title":"Novel roles for iron regulatory proteins in the adaptive response to iron deficiency","volume":"133","author":"Eisenstein","year":"2003","journal-title":"J. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1096\/fasebj.7.15.8262329","article-title":"Aconitase, a two-faced protein: Enzyme and iron regulatory factor","volume":"7","author":"Beinert","year":"1993","journal-title":"FASEB J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fphar.2014.00176","article-title":"The IRP\/IRE system in vivo: Insights from mouse models","volume":"5","author":"Wilkinson","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"17791","DOI":"10.1074\/jbc.M113.460253","article-title":"Each member of the poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin","volume":"288","author":"Leidgens","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13148","article-title":"Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy","volume":"509","author":"Mancias","year":"2014","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e46490","DOI":"10.7554\/eLife.46490","article-title":"Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates","volume":"8","author":"Cockman","year":"2019","journal-title":"Elife"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/CIRCULATIONAHA.116.021494","article-title":"Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans through Hypoxia-Inducible Factor-2alpha","volume":"133","author":"Dai","year":"2016","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood-2013-01-478065","article-title":"Erythrocytosis: The HIF pathway in control","volume":"122","author":"Franke","year":"2013","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1096\/fj.02-0445fje","article-title":"Widespread, hypoxia-inducible expression of HIF-2 in distinct cell populations of dierent organs","volume":"17","author":"Wiesener","year":"2003","journal-title":"FASEB J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1096\/fj.201800430R","article-title":"Hematopoietic hypoxia-inducible factor 2alpha deficiency ameliorates pathological retinal neovascularization via modulation of endothelial cell apoptosis","volume":"33","author":"Korovina","year":"2019","journal-title":"FASEB J."},{"key":"ref_78","first-page":"376","article-title":"Adipocyte-Specific Hypoxia-Inducible Factor 2alpha Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation","volume":"36","author":"Alexaki","year":"2015","journal-title":"Mol. Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.cell.2015.11.011","article-title":"SnapShot: Hypoxia-Inducible Factors","volume":"163","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Greenald, D., Jeyakani, J., Pelster, B., Sealy, I., Mathavan, S., and van Eeden, F.J. (2015). Genome-wide mapping of Hif-1\u03b1binding sites in zebrafish. BMC Genom., 16.","DOI":"10.1186\/s12864-015-2169-x"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e46401","DOI":"10.15252\/embr.201846401","article-title":"Inherent DNA-binding specificities of the HIF-1alpha and HIF-2alpha transcription factors in chromatin","volume":"20","author":"Smythies","year":"2019","journal-title":"EMBO Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fphys.2014.00003","article-title":"Primitive and definitive erythropoiesis in mammals","volume":"5","author":"Palis","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4939-7428-3_7","article-title":"Functional analysis of erythroid progenitors by colony-forming assays","volume":"1698","author":"Palis","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI110133","article-title":"Studies on the liver to kidney switch of erythropoietin production","volume":"67","author":"Zanjani","year":"1981","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1182\/blood-2007-10-115857","article-title":"Repression via the GATA box is essential for tissue-specific erythropoietin gene expression","volume":"111","author":"Obara","year":"2008","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"11254","DOI":"10.1038\/s41598-019-47766-5","article-title":"An immortalized cell line derived from renal erythropoietin producing (REP) cells demonstrates their potential to transform into myofibroblasts","volume":"9","author":"Sato","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Pan, X., Suzuki, N., Hirano, I., Yamazaki, S., Minegishi, N., and Yamamoto, M. (2011). Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025839"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/ncomms2950","article-title":"A mouse model of adult-onset anaemia due to erythropoietin deficiency","volume":"4","author":"Yamazaki","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2013010030","article-title":"Plasticity of renal erythropoietin-producing cells governs fibrosis","volume":"24","author":"Souma","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00424-015-1740-2","article-title":"Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis","volume":"468","author":"Suzuki","year":"2016","journal-title":"Pflugers Arch."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000183585","article-title":"Why the kidney?","volume":"41","author":"Erslev","year":"1985","journal-title":"Nephron"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ki.2009.470","article-title":"Functional evidence confirmed by histological localization: Overlapping expression of erythropoietin and HIF-2alpha in interstitial fibroblasts of the renal cortex","volume":"77","author":"Castrop","year":"2010","journal-title":"Kidney Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1681\/ASN.2014121184","article-title":"Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling","volume":"27","author":"Souma","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1192811","article-title":"Reactivation of hepatic EPO synthesis in mice after PHD loss","volume":"329","author":"Minamishima","year":"2010","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1582-4934.2011.01484.x","article-title":"Hypoxia-inducible factor 1\u2013mediated human GATA1 induction promotes erythroid differentiation under hypoxic conditions","volume":"16","author":"Zhang","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00018-019-03387-9","article-title":"A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin","volume":"77","author":"Tolonen","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00018-011-0679-5","article-title":"Roles of the human hypoxia-inducible factor (HIF)-3 variants in the hypoxia response","volume":"68","author":"Pasanen","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5603\/FHC.2013.0043","article-title":"The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer","volume":"51","author":"Baltaziak","year":"2013","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fnins.2019.00750","article-title":"Convulsive Stress Mimics Brain Hypoxia and Promotes the P-Glycoprotein (P-gp) and Erythropoietin Receptor Overexpression. Recombinant Human Erythropoietin Effect on P-gp Activity","volume":"13","author":"Merelli","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1136\/gutjnl-2013-305317","article-title":"Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB","volume":"63","author":"Sonnweber","year":"2014","journal-title":"Gut"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","article-title":"Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice","volume":"119","author":"Mastrogiannaki","year":"2012","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1074\/jbc.272.9.5375","article-title":"Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia","volume":"272","author":"Lee","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"21048","DOI":"10.1074\/jbc.M000636200","article-title":"Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency","volume":"275","author":"Mukhopadhyay","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"24147","DOI":"10.1074\/jbc.274.34.24147","article-title":"Identification of a hypoxia response element in the transferrin receptor gene","volume":"274","author":"Lok","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_113","first-page":"2691","article-title":"NCOA4 is regulated by HIF and mediates mobilization of murine hepatic iron stores after blood loss","volume":"136","author":"Li","year":"2020","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ki.2011.77","article-title":"Scar wars: Mapping the fate of epithelial-mesenchymal-myofibroblast transition","volume":"80","author":"Quaggin","year":"2011","journal-title":"Kidney Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1021\/acs.jmedchem.7b01686","article-title":"Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases","volume":"61","author":"Joharapurkar","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1172\/JCI82819","article-title":"DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys","volume":"126","author":"Chang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.yexcr.2017.05.004","article-title":"Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies","volume":"356","author":"Haase","year":"2017","journal-title":"Exp. Cell. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Na\u00efve Chronic Kidney Disease Patients Not on Dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 Study of Roxadustat to Treat Anemia in Non\u2013Dialysis-Dependant CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-na\u00efve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther. Apher. Dial."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000513103","article-title":"Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial","volume":"52","author":"Nangaku","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: A Phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000517053","article-title":"A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study","volume":"7","author":"Akizawa","year":"2021","journal-title":"Kidney Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1159\/000518071","article-title":"Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1159\/000518072","article-title":"Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese Patients with Renal Anemia Receiving Dialysis","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000519043","article-title":"Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients","volume":"52","author":"Akizawa","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ogawa, C., Tsuchiya, K., Tomosugi, N., and Maeda, K. (2020). A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197153"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000522071","article-title":"Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor","volume":"145","author":"Ogawa","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related Anemia in Non-dialysis Patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfaa204","article-title":"Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: Rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials1","volume":"36","author":"Eckardt","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of Molidustat in the Treatment of Anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000499111","article-title":"Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non\u2013Dialysis-Dependent CKD Pooled Results of Three Randomized Clinical Trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/1744-9987.13839","article-title":"Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan","volume":"26","author":"Nangaku","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/1744-9987.13724","article-title":"Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies","volume":"26","author":"Akizawa","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/ndt\/gfaa110","article-title":"The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: A meta-analysis","volume":"36","author":"Zheng","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bcp.15055","article-title":"Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis","volume":"88","author":"Zheng","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"746265","DOI":"10.3389\/fphar.2022.746265","article-title":"Efficacy and Safety of Daprodustat vs. rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis","volume":"13","author":"Fu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"573645","DOI":"10.3389\/fphar.2020.573645","article-title":"Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"105020","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs. epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis","volume":"159","author":"Zheng","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00228-022-03395-y","article-title":"Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: A meta-analysis of randomized clinical trials","volume":"78","author":"Fatima","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/3037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:23:44Z","timestamp":1760120624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/3037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":161,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24033037"],"URL":"https:\/\/doi.org\/10.3390\/ijms24033037","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}